reviewed april 2026|next review october 2026|88 physicians psi has verified|3 published studies
N-Acetyl Selank
N-Acetyl selank (NA-selank) is an N-acetylated derivative of the Russian-approved anxiolytic peptide selank, designed for improved metabolic stability, with no published studies under this specific compound name.
Evidence landscape: 3 published studies
0 published studies under this compound name.
- 3 Other research
Not FDA-approved. Not independently approved by any regulatory authority. The parent compound selank is approved in Russia as a prescription anxiolytic.
Available as a research compound from peptide suppliers. Not a registered pharmaceutical in any jurisdiction. Properties are extrapolated from the parent compound selank.
N-acetylated derivative of selank. The N-acetylation is a standard pharmaceutical modification to protect against aminopeptidase degradation, theoretically extending peptide half-life. Zero published studies exist under this specific compound name.
PSI Assessment
An N-acetylated derivative of selank designed for improved metabolic stability and potentially enhanced blood-brain barrier penetration, N-acetyl selank (NA-selank) has no published studies under this specific compound name. The parent compound selank is approved in Russia as a prescription anxiolytic, and the N-acetylation modification is a common pharmaceutical strategy to extend peptide half-life. Whether the acetylated form retains, enhances, or alters the parent compound's anxiolytic and immunomodulatory properties has not been established in any published research. NA-selank exists in the research peptide market based entirely on extrapolation from its parent molecule.
Zero published studies under this compound name. Properties extrapolated entirely from the parent compound selank. N-acetylation is a standard stability modification.
The theoretical mechanism is identical to selank (GABAergic modulation, BDNF upregulation, tuftsin-derived immunomodulation) with improved metabolic stability from N-terminal acetylation. The acetyl group protects against aminopeptidase degradation, theoretically extending the peptide half-life and improving absorption. Whether this modification alters receptor binding, potency, or the balance of anxiolytic versus immunomodulatory effects has not been studied.
What the evidence supports
N-acetylation is a well-established pharmaceutical modification that typically improves metabolic stability and extends peptide half-life. The parent compound selank has Russian regulatory approval as an anxiolytic with published clinical data. The structural modification is characterized.
What is not yet established
Whether NA-selank retains the anxiolytic and immunomodulatory properties of selank. Whether the N-acetylation alters potency, receptor selectivity, or the balance of effects. Pharmacokinetic profile, bioavailability, and half-life of the acetylated form. Any aspect of safety or efficacy specific to NA-selank rather than selank.
Research Evidence
No published research exists for NA-selank specifically. The findings below are derived from the parent compound selank.
Evidence by condition
No evidence dimensions can be assessed for NA-selank specifically. All research applies to the parent compound selank. Anxiety, cognitive enhancement, and immune modulation are extrapolated from parent data.
| Condition | Mechanism | Animal evidence | Human evidence | Replication |
|---|---|---|---|---|
| Anxiety | ||||
| Cognitive Enhancement | ||||
| Immune Modulation |
The parent compound selank has Russian regulatory approval as a prescription anxiolytic with published clinical data demonstrating anxiolytic effects through GABAergic modulation and BDNF upregulation.
All clinical evidence belongs to the parent compound. Whether the N-acetylated derivative retains these properties is entirely unvalidated.
N-acetylation is a well-characterized pharmaceutical modification that protects peptides against aminopeptidase degradation. The modification is expected to improve metabolic stability based on general peptide chemistry principles.
The pharmacological rationale for the modification is sound, but the specific effects on selank's receptor binding profile, potency, and duration of action have not been studied.
How N-Acetyl Selank Works
N-Acetyl selank (NA-selank) is a chemically modified version of the peptide selank, with an acetyl group (a small chemical tag) added to its N-terminus (the starting end of the peptide chain). This modification is a standard technique in peptide chemistry designed to prevent enzymes from breaking down the peptide too quickly, potentially extending how long it remains active in the body.
Same as Selank. Modulates GABA and serotonin systems to reduce anxiety without sedation. The N-acetyl group is added to protect the peptide from being broken down too quickly, potentially making it last longer and absorb better through the nose.
For a more detailed view of the biology, here is what researchers have observed at the molecular level.
NA-selank retains the tuftsin-derived core sequence of selank with N-terminal acetylation for improved resistance to aminopeptidase degradation. Proposed to enhance nasal mucosal absorption. Theoretical receptor pharmacology is identical to selank: modulates GABA-A (gamma-aminobutyric acid type A) receptor activity, enhances BDNF expression, and modulates IL-6 signaling. No pharmacokinetic or pharmacodynamic data exists for the acetylated form specifically.
What is N-Acetyl Selank being studied for?
Researchers are studying N-Acetyl Selank across several health conditions. Each condition below is labeled with the strength of evidence that exists for that specific use, not for N-Acetyl Selank overall. This means a compound can have human studies for one condition but only animal data for another.
Anxiety
·PreclinicalNo published studies for NA-selank specifically. Properties extrapolated from the parent compound selank, which has Russian regulatory approval as an anxiolytic.
Limitations: Zero published studies under this compound name. Whether the N-acetylation preserves, enhances, or diminishes the anxiolytic effects of selank is entirely unknown.
Cognitive Enhancement
·PreclinicalNootropic effects extrapolated from selank's BDNF upregulation. No independent data for the acetylated form.
Limitations: No published cognitive studies for NA-selank. Extrapolation from parent compound only.
Immune Modulation
·PreclinicalImmunomodulatory effects extrapolated from selank's tuftsin-derived activity. No independent data for the acetylated form.
Limitations: No published immunological studies for NA-selank. Whether acetylation alters the immunomodulatory profile is unknown.
Safety and Regulatory Status
FDA Status: Not FDA-approved. Not independently approved by any regulatory authority. The parent compound selank is approved in Russia as a prescription anxiolytic.
Availability: Available as a research compound from peptide suppliers. Not a registered pharmaceutical. Properties and safety profile are extrapolated from the parent compound selank.
Class context: No independent safety data for NA-selank. The parent compound selank is well-tolerated in Russian clinical use with minimal reported side effects. N-acetylation is a common peptide modification that does not typically introduce new toxicity.
NA-selank has no independent safety data. The safety profile is entirely extrapolated from the parent compound selank, which is well-tolerated in Russian clinical use. N-acetylation is a standard pharmaceutical modification that does not typically introduce new toxicity, but the specific pharmacokinetics of the acetylated form in humans are unknown.
Questions and Comparisons
Questions the evidence raises for a N-Acetyl Selank discussion.
Comparison and Related Research
NA-selank is most often compared with its parent compound and other Russian-developed neuropeptides.
Head-to-head comparisons
Full research comparisons covering N-Acetyl Selank and another peptide side by side.
N-Acetyl Selank vs Selank
NA-Selank is the N-acetyl form with potentially better nasal absorption. Selank is the original with more research. What the modification changes.
View full comparisonRelated compounds
Frequently Asked Questions
References
Each citation links to the original study on PubMed, the U.S. National Library of Medicine database.
- 1.Animal study on the parent compound selank demonstrating improved learning and memory performance in a conditioned avoidance task. Rats treated with the peptide showed optimized adaptive behavior under stress. NA-Selank is the N-acetylated form of selank, designed to enhance metabolic stability while preserving the parent compound's anxiolytic and nootropic profile.Kozlovskii II & Danchev ND, 2003 in Neurosci Behav Physiol. View on PubMed
- 2.Early preclinical study characterizing the anxiolytic properties of selank (TP-7) and its parent molecule taftsin. The research documented effects on serotonin metabolism in the brain, establishing the neurochemical basis for the anxiety-reducing properties that both selank and its N-acetylated derivative are investigated for.Seredenin SB et al., 1995 in Eksp Klin Farmakol. View on PubMed
- 3.Human study examining immune system changes in patients with anxiety-related conditions who received the parent compound selank. Documented shifts in immune markers alongside anxiolytic effects, suggesting a dual mechanism affecting both neurological and immune function. This immunomodulatory profile is expected to be shared by NA-Selank based on structural similarity.Uchakina ON et al., 2008 in Zh Nevrol Psikhiatr Im S S Korsakova. View on PubMed
- 4.Investigation of Phase II metabolic pathways including N-acetylation, which is the chemical modification that distinguishes NA-Selank from its parent compound. N-acetylation is a well-characterized metabolic process that can alter peptide stability and bioavailability, providing the pharmacological rationale for the N-acetylated derivative.Spriggs S et al., 2018 in Toxicol Lett. View on PubMed
Medical Disclaimer
This content is for educational and informational purposes only and does not constitute medical advice. The information presented reflects published research as indexed by PSI and should not be used to make treatment decisions. Always consult a qualified healthcare provider before starting, stopping, or modifying any treatment.